Advertisement

ADVERTISEMENT

outcomes research

Research in Review
Monotherapy Improves Outcomes in Metastatic Breast Cancer With BRCA Mutation
08/14/2017
JCP Editors
An immuno-agent improves progression-free survival (PFS) and lowers the risk of death for patients with human epidermal growth factor 2 (HER2)-negative metastatic breast cancer and a germline BRCA mutation, according...
An immuno-agent improves progression-free survival (PFS) and lowers the risk of death for patients with human epidermal growth factor 2 (HER2)-negative metastatic breast cancer and a germline BRCA mutation, according...
An...
08/14/2017
Journal of Clinical Pathways
Research in Review
Pediatric APL Outcomes Improved By Arsenic Trioxide Consolidation
08/03/2017
JCP Editors
Consolidation with arsenic trioxide allows for decreased anthracycline dosing while maintaining survival rates and a low risk of relapse in pediatric patients with acute promyelocytic leukemia (APL), according to a...
Consolidation with arsenic trioxide allows for decreased anthracycline dosing while maintaining survival rates and a low risk of relapse in pediatric patients with acute promyelocytic leukemia (APL), according to a...
...
08/03/2017
Journal of Clinical Pathways
Research in Review
Dose Escalation of CML Treatment Improves Molecular Response Rates
08/02/2017
JCP Editors
Patients with chronic myeloid leukemia (CML) in the chronic phase may achieve molecular response with safe and effective treatment dose escalation, according to a recent study. ----- Related Content CML Mutations...
Patients with chronic myeloid leukemia (CML) in the chronic phase may achieve molecular response with safe and effective treatment dose escalation, according to a recent study. ----- Related Content CML Mutations...
...
08/02/2017
Journal of Clinical Pathways
Research in Review
Second TKI Discontinuation Attempt Safe in Patients With CML
07/27/2017
JCP Editors
Patients with chronic myeloid leukemia (CML) who attempt to discontinue tyrosine kinase inhibitor (TKI) therapy for a second time after a first unsuccessful attempt have strong treatment-free remission rates,...
Patients with chronic myeloid leukemia (CML) who attempt to discontinue tyrosine kinase inhibitor (TKI) therapy for a second time after a first unsuccessful attempt have strong treatment-free remission rates,...
...
07/27/2017
Journal of Clinical Pathways
Research in Review
New Therapy Highly Effective in Treatment-Resistant CLL
07/18/2017
JCP Editors
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A...
07/18/2017
Journal of Clinical Pathways
Research in Review
CAR-T Therapy Highly Effective in Treatment-Resistant CLL
07/18/2017
JCP Editors
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A...
07/18/2017
Journal of Clinical Pathways
Research in Review
Continued Nivolumab After Progression May Improve Outcomes in Melanoma
07/03/2017
JCP Editors
Patients with advanced melanoma who are treated with nivolumab after their first disease progression may experience tumor response without compromising safety, according to an original investigation published in JAMA...
Patients with advanced melanoma who are treated with nivolumab after their first disease progression may experience tumor response without compromising safety, according to an original investigation published in JAMA...
...
07/03/2017
Journal of Clinical Pathways
Research in Review
NSCLC Treatment Patterns, OS Data Aids Clinical Practice Benchmark Initiatives
06/26/2017
JCP Editors
Results of a recent study offer insight into the effects of shifting treatment patterns of non-small cell lung cancer (NSCLC) treatment on patient outcomes, and for furthering community oncology benchmark...
Results of a recent study offer insight into the effects of shifting treatment patterns of non-small cell lung cancer (NSCLC) treatment on patient outcomes, and for furthering community oncology benchmark...
...
06/26/2017
Journal of Clinical Pathways
Research in Review
DLBCL Survival Outcomes Improved With Combination Therapy
06/22/2017
JCP Editors
Patients with diffuse large B-cell lymphoma (DLBCL) benefit from improved survival outcomes when treated with a combination therapy rather than monotherapy, according to research presented at the 22nd Congress of the...
Patients with diffuse large B-cell lymphoma (DLBCL) benefit from improved survival outcomes when treated with a combination therapy rather than monotherapy, according to research presented at the 22nd Congress of the...
...
06/22/2017
Journal of Clinical Pathways
Research in Review
CAR T-Cells Improve Outcomes in Multiple Myeloma
06/13/2017
JCP Editors
Multiple studies have demonstrated positive results for chimeric antigen receptor (CAR) T-cells in treating relapsed and refractory multiple myeloma, according to presentations at the 2017 ASCO Annual Meeting (June...
Multiple studies have demonstrated positive results for chimeric antigen receptor (CAR) T-cells in treating relapsed and refractory multiple myeloma, according to presentations at the 2017 ASCO Annual Meeting (June...
...
06/13/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

Psych Congress Regionals
July 18 ⁠–⁠ July 19
Advances in Inflammatory Bowel Disease Regionals
July 19 ⁠–⁠ July 20
July 24 ⁠–⁠ July 26
APP Institute Inflammatory Bowel Disease
July 26 ⁠–⁠ July 27
July 27 ⁠–⁠ July 28
July 27 ⁠–⁠ July 28
Psych Congress Regionals
August 8 ⁠–⁠ August 9
August 14 ⁠–⁠ August 17
APP Institute Dermatology
August 16 ⁠–⁠ August 17
August 16 ⁠–⁠ August 18
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use